Loading clinical trials...

Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery | Clinical Trials | Clareo Health

TERMINATEDPHASE3

Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Statin Polyp Prevention Trial in Patients With Resected Colon Cancer

NCT01011478•NSABP Foundation Inc

View on ClinicalTrials.gov

Summary

RATIONALE: Rosuvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving rosuvastatin after surgery may kill any tumor cells that remain after surgery. It may also keep polyps from forming or colon cancer from coming back. It is not yet known whether rosuvastatin is more effective than a placebo in treating colon cancer that was removed by surgery. PURPOSE: This randomized phase III trial is studying rosuvastatin to see how well it works compared with placebo in treating patients with stage I or stage II colon cancer that was removed by surgery.

Detailed Description

OBJECTIVES: Primary * To compare the effect of rosuvastatin vs placebo on the 5-year occurrence of adenomatous polyps of the colon or rectum, metachronous colorectal carcinoma, or colon cancer recurrence (APMC+R) in patients with resected stage I or II colon cancer. Secondary * To determine whether the effect of rosuvastatin vs placebo is of the same magnitude in patients taking aspirin (regardless of dose) compared to patients not taking aspirin. * To determine whether taking aspirin (regardless of dose) vs no aspirin will decrease the occurrence or APMC+R and, if there is an effect, to explore the relationship to dose. * To determine the effect of rosuvastatin in patients with familial colorectal cancer. * To determine the effect of rosuvastatin in patients with microsatellite unstable tumors (i.e., tumors displaying loss of MLH1 or MSH2 expression by IHC). * To determine the relationship between rosuvastatin therapy and features of colorectal adenomas as well as the size and number of colorectal adenomas. * To compare the time to APMC+R in patients treated with rosuvastatin vs placebo. * To compare the disease-free survival of patients treated with rosuvastatin vs placebo. * To compare the overall survival of patients treated with rosuvastatin vs placebo. * To compare the rate of recurrence of colon cancer in patients treated with rosuvastatin vs placebo. * To compare the rate of second non-colorectal primary cancers in patients treated with rosuvastatin vs placebo. * To determine the effect of rosuvastatin on health-related quality of life, global quality of life, and self-reported symptoms. * To compare the incidence and severity of adverse events associated with rosuvastatin vs placebo. * To assess relevant tumor and blood markers that may affect the metabolism, activity, or effect of the study drugs, such as HMG-CoA reductase, UGT1A6, P450-2C9, PTGS2 (COX-2), and other possible markers. OUTLINE: This is a multicenter study. Patients are stratified according to family history of a first-degree relative with colorectal cancer (yes vs no), intended aspirin dose (none vs 81 mg vs 325 mg), and adjuvant therapy for colon cancer (yes vs no). Patients are randomized to 1 of 2 treatment arms. * Group 1: Patients receive oral placebo once daily for 5 years. * Group 2: Patients receive oral rosuvastatin once daily for 5 years. Patients may complete a quality-of-life questionnaire at baseline and at 6, 12, 36, 60, and 84 months. Tumor tissue, serum, and blood samples may be collected periodically for biomarker and other analyses. After completion of study treatment, patients are followed up periodically for up to 2 years.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
•Patients must have the ability to swallow oral medication.
•Patients must have resected adenocarcinoma of the colon staged as American Joint Committee on Cancer (AJCC) Stage 0, I, II, or III.
•Patients must have had surgical resection of the colon adenocarcinoma with curative intent within 1 year prior to randomization. (Laparoscopically-assisted colectomy is permitted.)
•Patients must have completed any adjuvant therapy prior to randomization.
•Patients who are taking cardioprotective low-dose aspirin at study entry must not have clinically significant toxicity, as determined by the investigator, that precludes continuation of aspirin, and the patient must be willing to continue aspirin therapy (81 mg or 325 mg) throughout study therapy.
•Colonoscopy requirements within 180 days prior to randomization:
•The patient must have either undergone a preoperative or postoperative documented colonoscopy to the cecum (or small bowel anastomosis) with adequate bowel preparation.
•All observed polyps must have been removed. (Polyps can be removed during colonoscopy or surgery performed prior to randomization.)
•Postoperative serum creatinine performed within 90 days prior to randomization must be less than or equal to 1.5 x upper limit of normal (ULN) for the lab.
+3 more criteria

Exclusion Criteria

•Tumor with the distal border located less than 12 cm from the anal verge.
•Total colectomy or total proctocolectomy.
•Classic Familial Adenomatous Polyposis, Attenuated Familial Adenomatous Polyposis (i.e., 20 or more adenomas, either synchronous or metachronous), or Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome).
•Malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, resection of the stomach or small bowel, or other disease significantly affecting gastrointestinal function.
•History of documented upper GI bleeding or upper GI ulcerative disease.
•Statin use within 30 days prior to randomization.
•Hyperlipidemia with clinical indication for statin therapy or other prescribed medication. Determination of acceptable fasting lipid values, within 90 days prior to randomization, should be in accordance with current dyslipidemia management guidelines.
•Unwillingness to discontinue chronic use of nonsteroidal antiinflammatory drugs (NSAIDs) (other than cardioprotective low-dose aspirin 81 mg or 325 mg) prior to randomization.
•Anticipated need for chronic use of NSAIDs (other than cardioprotective low-dose aspirin 81 mg or 325 mg).
•Inadequately treated hypothyroidism, as determined by the investigator.
+4 more criteria

Locations (587)

Regional Medical Center

Anniston, Alabama, United States

Providence Cancer Center at Providence Hospital

Mobile, Alabama, United States

Hembree Mercy Cancer Center at St. Edward Mercy Medical Center

Fort Smith, Arkansas, United States

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Kaiser Permanente Medical Center - Anaheim/Orange County

Anaheim, California, United States

Kaiser Permanente - Deer Valley

Antioch, California, United States

Kaiser Permanente Medical Center - Baldwin Park

Baldwin Park, California, United States

Kaiser Permanente Medical Center - Bellflower

Bellflower, California, United States

East Bay Radiation Oncology Center

Castro Valley, California, United States

Key Dates

Start Date

March 1, 2010

Primary Completion Date

December 1, 2014

Completion Date

February 1, 2015

Last Updated

August 16, 2023

Enrollment

406

ACTUAL participants

Conditions

Colorectal CancerPrecancerous Condition

Interventions

rosuvastatin

DRUG

placebo

OTHER

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768

Metastatic Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8+2 more

View study

RECRUITINGPHASE1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 16, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Inclusion Criteria

Exclusion Criteria

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease